Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. Perseus Proteomics Inc. has a joint research agreement with ASKA Pharmaceutical Co., Ltd. for the development of new antibody drugs and therapeutic drugs for specific disease areas. Perseus Proteomics Inc. was incorporated in 2001 and is headquartered in Tokyo, Japan.
Frequently asked questions
What sector does Perseus Proteomics Inc. (4882) operate in?
Perseus Proteomics Inc. belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is Perseus Proteomics Inc. (4882) current stock price?
As of the latest data, Perseus Proteomics Inc. stock price is ¥147, with a previous close of ¥147.
What is Perseus Proteomics Inc. (4882) current market capitalization?
Perseus Proteomics Inc. market cap is approximately 2.50 billion.
What is Perseus Proteomics Inc. (4882) Earnings Per Share (EPS)?
The trailing EPS is -¥48.
What is Perseus Proteomics Inc. (4882) EBITDA?
Perseus Proteomics Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -169.84 million.
Does Perseus Proteomics Inc. (4882) pay dividends?
No. Perseus Proteomics Inc. does not pay a dividend.
What is Perseus Proteomics Inc. (4882) beta (volatility) score?
Perseus Proteomics Inc. has a beta of 0.310, indicating lower volatility than the overall market.
